Please ensure Javascript is enabled for purposes of website accessibility

Why Celldex Therapeutics, Inc. Stock Jumped Higher Again Today

By Brian Orelli, PhD – Nov 14, 2016 at 3:58PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Seeming anything -- including preclinical data -- will spark shares of the beaten-down biotech.

Image source: Getty Images.

What happened

Shares of Celldex Therapuetics (CLDX -3.60%) are up 10.5% at 3:37 p.m. EST after the biotech presented data on CDX-1140 at the Society for Immunotherapy of Cancer (SITC) annual meeting on Saturday.

So what

You're forgiven if you've never heard of CDX-1140; the drug hasn't started clinical studies yet. The preclinical data presented at SITC showed that the drug could bind to its target, CD40, turning on the receptor that activates the immune system, which can then attack a tumor. Celldex is completing the preclinical development for CDX-1140, with plans to start clinical development next year. The ultimate plan is to test CDX-1140 in combination with other immunotherapies or conventional cancer treatments.

Normally preclinical data wouldn't send shares up by a double-digit percentage, but these aren't ordinary times. The biotech sector is still enjoying some post-election euphoria since Hillary Clinton won't be able to lower drug prices. And for Celldex specifically, the biotech has been quite volatile lately as it waits for data from its two lead drugs, glembatumumab vedotin and varlilumab. Shares made another double-digit jump last week after what appeared to be a news-less earnings report.

Now what

Long-term investors can ignore the moves up -- and likely some future news-less moves down -- because none of it really matters to the long-term valuation, which will be defined by whether glembatumumab vedotin and varlilumab make it to market.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Celldex Therapeutics. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.